Logo image of SAGE

SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis

NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock

6.94  -0.14 (-1.98%)

After market: 6.94 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SAGE. SAGE was compared to 572 industry peers in the Biotechnology industry. SAGE has a great financial health rating, but its profitability evaluates not so good. SAGE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SAGE has reported negative net income.
SAGE had a negative operating cash flow in the past year.
In the past 5 years SAGE reported 4 times negative net income.
SAGE had negative operating cash flow in 4 of the past 5 years.
SAGE Yearly Net Income VS EBIT VS OCF VS FCFSAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M -600M

1.2 Ratios

SAGE has a Return On Assets (-54.24%) which is comparable to the rest of the industry.
With a Return On Equity value of -61.18%, SAGE perfoms like the industry average, outperforming 59.47% of the companies in the same industry.
Industry RankSector Rank
ROA -54.24%
ROE -61.18%
ROIC N/A
ROA(3y)-41.91%
ROA(5y)-32.08%
ROE(3y)-45.58%
ROE(5y)-35.9%
ROIC(3y)N/A
ROIC(5y)N/A
SAGE Yearly ROA, ROE, ROICSAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60

1.3 Margins

With an excellent Gross Margin value of 91.75%, SAGE belongs to the best of the industry, outperforming 93.81% of the companies in the same industry.
SAGE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SAGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.82%
GM growth 5YN/A
SAGE Yearly Profit, Operating, Gross MarginsSAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SAGE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SAGE has been increased compared to 5 years ago.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SAGE Yearly Shares OutstandingSAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
SAGE Yearly Total Debt VS Total AssetsSAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -3.61, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
SAGE has a Altman-Z score (-3.61) which is comparable to the rest of the industry.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.61
ROIC/WACCN/A
WACC11.11%
SAGE Yearly LT Debt VS Equity VS FCFSAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

SAGE has a Current Ratio of 10.02. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
SAGE has a Current ratio of 10.02. This is amongst the best in the industry. SAGE outperforms 80.35% of its industry peers.
SAGE has a Quick Ratio of 10.02. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.02, SAGE belongs to the top of the industry, outperforming 80.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.02
Quick Ratio 10.02
SAGE Yearly Current Assets VS Current LiabilitesSAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.80% over the past year.
The Revenue has grown by 833.32% in the past year. This is a very strong growth!
Measured over the past years, SAGE shows a decrease in Revenue. The Revenue has been decreasing by -0.87% on average per year.
EPS 1Y (TTM)37.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.6%
Revenue 1Y (TTM)833.32%
Revenue growth 3Y-57.35%
Revenue growth 5Y-0.87%
Sales Q2Q%337.08%

3.2 Future

SAGE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.36% yearly.
Based on estimates for the next years, SAGE will show a very strong growth in Revenue. The Revenue will grow by 29.60% on average per year.
EPS Next Y34.99%
EPS Next 2Y27.04%
EPS Next 3Y19.81%
EPS Next 5Y13.36%
Revenue Next Year-39.16%
Revenue Next 2Y16.3%
Revenue Next 3Y31.71%
Revenue Next 5Y29.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SAGE Yearly Revenue VS EstimatesSAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SAGE Yearly EPS VS EstimatesSAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SAGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAGE Price Earnings VS Forward Price EarningsSAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAGE Per share dataSAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as SAGE's earnings are expected to grow with 19.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.04%
EPS Next 3Y19.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SAGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (1/21/2025, 8:25:25 PM)

After market: 6.94 0 (0%)

6.94

-0.14 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2024-10-29/amc
Earnings (Next)02-12 2025-02-12/amc
Inst Owners89.88%
Inst Owner Change-0.07%
Ins Owners0.59%
Ins Owner Change2.38%
Market Cap424.52M
Analysts66.4
Price Target9.12 (31.41%)
Short Float %8.97%
Short Ratio3.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.85%
Min EPS beat(2)-0.48%
Max EPS beat(2)2.18%
EPS beat(4)1
Avg EPS beat(4)-10.9%
Min EPS beat(4)-38.16%
Max EPS beat(4)2.18%
EPS beat(8)2
Avg EPS beat(8)-8.19%
EPS beat(12)5
Avg EPS beat(12)-5.04%
EPS beat(16)7
Avg EPS beat(16)318.47%
Revenue beat(2)1
Avg Revenue beat(2)1.82%
Min Revenue beat(2)-4.11%
Max Revenue beat(2)7.74%
Revenue beat(4)3
Avg Revenue beat(4)15.78%
Min Revenue beat(4)-4.11%
Max Revenue beat(4)34.14%
Revenue beat(8)5
Avg Revenue beat(8)10.5%
Revenue beat(12)6
Avg Revenue beat(12)-0.21%
Revenue beat(16)7
Avg Revenue beat(16)111.82%
PT rev (1m)-5%
PT rev (3m)-38.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.57%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)8.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.99
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)-6.83
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-5.23
FCFYN/A
OCF(TTM)-5.23
OCFYN/A
SpS1.74
BVpS9.02
TBVpS9.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.24%
ROE -61.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.75%
FCFM N/A
ROA(3y)-41.91%
ROA(5y)-32.08%
ROE(3y)-45.58%
ROE(5y)-35.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.82%
GM growth 5YN/A
F-Score6
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.35%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.02
Quick Ratio 10.02
Altman-Z -3.61
F-Score6
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)43.68%
Cap/Depr(5y)78.95%
Cap/Sales(3y)6.23%
Cap/Sales(5y)20.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.6%
EPS Next Y34.99%
EPS Next 2Y27.04%
EPS Next 3Y19.81%
EPS Next 5Y13.36%
Revenue 1Y (TTM)833.32%
Revenue growth 3Y-57.35%
Revenue growth 5Y-0.87%
Sales Q2Q%337.08%
Revenue Next Year-39.16%
Revenue Next 2Y16.3%
Revenue Next 3Y31.71%
Revenue Next 5Y29.6%
EBIT growth 1Y43.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.97%
EBIT Next 3Y19.25%
EBIT Next 5Y13.65%
FCF growth 1Y25.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.66%
OCF growth 3YN/A
OCF growth 5YN/A